March 3, 2017
MEMBER/CENTER HIGHLIGHTS
Reversing Enzalutamide Resistance Offers Promise for Treating Advanced Prostate Cancer
Lerner Research Institute - Feb 13, 2017
Dr. Nima Sharifi
Nima Sharifi
A research team led by  Nima Sharifi, MD, Co-Leader, GU Malignancies Program, Case Comprehensive Cancer Center, and Kendrick Family Endowed Chair for Prostate Cancer Research, has uncovered a cause of prostate cancer drug resistance and was able to reverse the resistance in human prostate cancer cells grown in a mouse model.

Resistance to prostate cancer drugs is a common clinical problem. As prostate cancer cells need male hormones, or androgens, to grow, standard therapies like androgen deprivation (or "medical castration") can be effective for advanced prostate cancer, but they typically stop working at some point. When standard therapies fail, patients are often then treated with a potent cancer drug called enzalutamide. An androgen receptor blocker, enzalutamide stunts tumor growth by keeping male hormones within prostate tumor cells from binding to and activating an androgen receptor protein. 

Unfortunately, enzalutamide does not work indefinitely, and tumors eventually become resistant to it as well.
As published in  eLife [ Li J. eLife. 2017], Dr. Sharifi's team discovered a complex cascade of events - a "metabolic switch"- that occurs when androgen receptors are blocked with enzalutamide. The drug causes levels of an enzyme called 11βHSD2 to fall, which creates a surplus of the stress hormone cortisol in the tumor cells. This extra cortisol activates its own receptor protein complex, which then takes on the role of the disabled androgen receptor and instructs cancer cells to make more androgens.

Because blocking cortisol from its receptor is not compatible with life, the team searched for other ways to turn off this metabolic switch. Remarkably, they found that restoring levels of 11βHSD2 reversed enzalutamide resistance. While futures studies will need to determine how to increase 11βHSD2 levels safely, this discovery holds great promise for patients who are resistant to all current treatments.

First author on the study was  Jianneng Li, PhD, a postdoctoral fellow in Dr. Sharifi's lab. Cancer Center members Cristina Magi-Galluzzi, Jorge Garcia, and Eric Klein were co-authors on this study. 
MARK YOUR CALENDARS
Make the Magic Fundraiser to Support Camp Kesem
Apr 1, 2017 | Cleveland, OH
Camp Kesem logo Camp Kesem at Case Western Reserve University, an organization dedicated to supporting children through and beyond their parent's cancer, announces its annual Make the Magic event on Saturday, April 1, 2017 from 6-9p at the Tudor Arms Hotel. The event will include a three-course meal, words from a camper and camper parent, and the opportunity to experience the impact Camp Kesem has had on the families and communities.

Funds raised during this annual fundraising night of dinner, philanthropy, and entertainment will help provide year-long peer support and send 60 campers to camp from August 7-12. more>
Hyaluronan Cleveland 2017
Jun 11-15, 2017 | InterContinental Hotel
Registration is open for Hyaluronan 2017 , the 11th International Conference on Hyaluronan, sponsored by the International Society for Hyaluronan Sciences  (ISHAS), Jun 11-15, 2017 to be held at the InterContinental Hotel. 

The conference will honor the scientific contributions of Raija and Markku Tammi for their discoveries on the pathological regulation of hyaluronan metabolism, especially pertaining to cancer development. The conference will consist of 10 sessions, starting with a "translational focus" on the applications of Hyaluronan and Hyaluronidase in medicine (This activity has been approved for AMA PRA Category 1 Credits™.) and continue with topics on structure and metabolism, development and signal transduction, chronic inflammatory diseases, and cancer. more>
International Cancer Education Conference
Sep 13-15, 2017 | Cleveland, OH
ICEC 2017 The International Cancer Education Conference is the only meeting in North America totally dedicated to cancer education - ranging from medical professionals to patients and community education.  We invite you to submit an abstract and attend this meeting of national and international specialists in cancer education, survivorship and palliative care focused on advocacy, scientific investigation, program and curriculum development, skill training, and evaluation.  National leaders will be presenting special programs on grant writing (National Cancer Institute), cancer and the elderly (Cancer and Aging Research Group), surgical oncology (American College of Surgeons), plus dedicated mentoring opportunities will be available to present to content experts. The deadline for abstracts is March 6, 2017 for workshops and April 3, 2017 for oral and poster presentations.

GvHD National Symposium 2017
Oct 13, 2017 | Columbus, OH
The GvHD National Symposium focuses on cutting edge research and new treatments, and consists of two tracks: one designed for physicians and other health care professionals, and one for bone marrow transplant (BMT) survivors, their families and caregivers. The Meredith A. Cowden Foundation in collaboration with the Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, and Cleveland Clinic Taussig Cancer Institute, created this annual event to raise awareness about GvHD, to promote research to further our understanding of its cause, and to review cutting edge approaches to prevention and treatment. Registration will open soon. 
CASE CCC IN THE NEWS
Fox 8 - Mar 1, 2017
A high-risk cancer patient has renewed hope for a healthy future thanks to a clinical trial at University Hospitals Seidman Cancer Center..."Hopefully, we'll achieve the goal of safety and increase survival," said Dr. Michael Gibson, Case Comprehensive Cancer Center, an oncologist at University Hospitals. "He is certainly a very brave and giving individual. The likelihood of a tumor coming back is less than with standard treatment. 
Cancer Letter - Feb 24, 2017
The new Cleveland Clinic Taussig Cancer Center will begin welcoming patients March 6.  The 377,000-square-foot facility, estimated at $276 million, will house all outpatient cancer treatment services in one location. The seven-story cancer building is located on the north side of Carnegie Avenue between East 102nd and 105th Streets.  The building, designed by William Rawn Associates, Architects, Inc. and Stantec Architecture, is organized by cancer type, allowing patients to now have all of their appointments in one area where clinical caregivers come to the patient. " As one of the nation's most progressive cancer centers, the new Taussig Cancer Center will provide a seamless, personalized experience," said Brian Bolwell, chairman of the Cleveland Clinic Taussig Cancer Institute. "Our design priorities of reduced wait times, improved patient flow, multidisciplinary clinics and a healing environment, combined with a commitment to cancer research, will deliver the best possible care and support for our patients."
FUNDING OPPORTUNITIES
Opportunities for Pilot Projects from VeloSano Bike to Cure
DEADLINE: March 6, 2017
With the generous support from VeloSano Bike to Cure 2016, the Case Comprehensive Cancer Center is providing seed funding for the initiation of novel projects aligned with at least one of the seven Research Programs (GI Cancer Genetics, Molecular Oncology, GU Malignancies, Hematopoietic and Immune Cancer Biology, Developmental Therapeutics, Cancer Imaging, or Cancer Prevention, Control, & Population Research) or the Brain Tumor or Breast Cancer research initiatives within the Center. Highly innovative and impactful proposals are sought that will generate key data for larger, nationally competitive grants that interface with the Strategic Plan of the aligned program(s). Proposals must include collaborative, multi-investigator projects.  In addition, projects that focus on renal cancer biology, disparities research, brain tumors, or drug discovery and screening are particularly encouraged.

Eligibility for funds will be restricted to lead PIs that are Center members who participated in VeloSano Bike to Cure 2016 (rider, virtual rider, or volunteer). In addition, the lead PI of the application must not be eligible for CCF VeloSano funding. Co-PIs and Co-investigators are not required to have been VeloSano participants. All awardees (PIs and co-investigators) will be expected to participate in VeloSano 2017 as well as to present their research progress when requested by the Case Comprehensive Cancer Center.
Cancer Center Summer Training for Medical Students
Deadline: Mar 31, 2017
The Case Comprehensive Cancer Center is looking for medical students interested in summer research opportunities.

There are 9 openings available, with 5 supported by the Brian Werbel Memorial Fund and 4 by the Case Comprehensive Cancer Center.
Details:
  • Completed application and reference letter due by: Friday, March 31, 2017
  • Awardees must be conducting cancer research with a Case Comprehensive Cancer Center member. View list of members.
  • Those receiving the Brian Werbel Memorial Fund awards must attend the annual golf outing.
Contact Damian Junk at  damian.junk@case.edu with any questions.
Damon Runyon Innovation Award
Deadline: Jul 6, 2017
The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer.
The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field.
Case CCC Funding for Pilot/Phase I Clinical Trials
Deadline: Rolling 
The Case CCC is encouraging investigators to submit Letters of Intent (LOI) for Early Phase Clinical Research Support (EPCRS) funding. These in-house funds are available for the conduct of early phase clinical trials of relatively short duration. Priority will be given to trials which are developed jointly between UH and CCF with planned accrual at both institutions.

The proposals are being accepted on a rolling basis subject to availability of funds.

Please direct any questions and/or submit LOIs to Katarzyna Karelus, Case CCC Clinical Research Office,  katarzyna.karelus@case.edu, 216.844.4176.
NIH BULLETIN- Notices and Funding Opportunities
EVENTS
Mon, Mar 6
Cancer Center Research Chalk Talk
1p WRB 3-136
Tues, Mar 7
Radiation Oncology Grand Rounds
Julia Manzerova, MD, PhD
5th year resident, Stich Radiation Oncology Center, New York Presbyterian Hospital
"Big data in (rare) cancer research: the case of male breast cancer"
8:10a Lerner B-151

THOR Seminar
David Wald, MD, PhD
Assistant Professor, Clinical Pathology, CWRU/UH
1p R3-027

Cancer Center Research in Progress 
Helen Moinova, PhD
Instructor, Markowitz Lab
Div. of Hematology and Oncology, CWRU/UH
"Novel Markers for Detection Of Barrett's Esophagus And Esophageal Adenocarcinoma"
3p WRB 3-136
Wed, Mar 8
Hem/Onc Div Res Conf
8a Lerner B-151

PRCHN Seminar
Amy Bush Stevens, MSW, MPH
Health Policy Institute of Ohio
"Tobacco use in Ohio: Opportunities for policy, systems change and research"
12p PRCHN Conf Rm
Thurs, Mar 9
Developmental Therapeutics Journal Club
9a R4-013

Case CCC VeloSano Team Happy Hour/Meet & Greet 
4:30-6p Tavern of Little Italy
Fri, Mar 10
2017 St. Baldrick's "Shave It Off!"
6a-6p  UH Rainbow Babies & Children's Hospital Performance Area

Hem/Onc Fellows
8a Breen Conf Rm

TCI Grand Rounds
8a R3/002-003 Cleveland Clinic
Tues, Mar 14
THOR Seminar
Peter Mazzone, MD, MPH
Staff, Pulmonary Medicine, Cleveland Clinic
1p R3-027

Cancer Biology Seminar
Shuvojit Banerjee, PhD
Research Associate, Silverman Lab, Cancer Biology, Cleveland Clinic
"DNA methyltransferase Inhibitors target lung cancer cells by activating the IFN-regulated OAS-RNase L pathway"
2p NC1-202 

Cancer Center Research in Progress Seminar
Wang Lab, Div. of Hematology and Oncology, CWRU/UH
3p WRB 3-136
Wed, Mar 15
Hem/Onc Div Res Conf
8a Lerner B-151
Thurs, Mar 16
Developmental Therapeutics Journal Club
9a R4-013
Fri, Mar 17
1st Annual Cancer Disparities Symposium: Building Bridges to Address Cancer Disparities
Wolstein Research Bldg
8a-3:15p

Taussig Cancer Institute Grand Rounds
Sumanta Pal, MD
City of Hope
"Renal Cell Carcinoma: A 2017 Update"
8a R3/002-003

ADDITIONAL UPCOMING SYMPOSIUMS & EVENTS

2017 Multidisciplinary Head and Neck Cancer Update
Mar 10-11, 2017
Portofino Bay Resort at Universal Studios
Orlando, FL
1st Annual Cancer Disparities Symposium: Building Bridges to Address Cancer Disparities
Mar 17, 2017
Wolstein Research Bldg

NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™
Mar 23-25, 2017
Rosen Shingle Creek
Orlando, FL

CWRU/ACS Colleges Against Cancer -Cancer Research Fair 
4-6p Hovorka Auditorium, CWRU Campus

AACR Annual Meeting 2017
Apr 1-5, 2017
Walter E. Washington Convention Center
Washington, DC

GvHD National Symposium
Oct 13, 2017
Grand Event Center, Columbus, OH
PREVIOUSLY ANNOUNCED OPPORTUNITIES

Case Comprehensive Cancer Center 
11100 Euclid Avenue, Wearn152
Cleveland, OH 44106-5065